Ameriprise
KYTX icon

Ameriprise’s Kyverna Therapeutics KYTX Stock Holding History

Ameriprise’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,882
Closed -$77.3K – 4234
2025
Q3 		$77.3K Buy
+12,882
New +$51.5K ﹤0.01% 3990
2025
Q1 		– Sell
-190,383
Closed -$712K – 4167
2024
Q4 		$712K Buy
190,383
+67,606
+55% +$324K ﹤0.01% 3394
2024
Q3 		$600K Buy
122,777
+4,786
+4% +$36.9K ﹤0.01% 3420
2024
Q2 		$885K Buy
117,991
+81,408
+223% +$1.24M ﹤0.01% 3197
2024
Q1 		$909K Buy
+36,583
New +$1.02M ﹤0.01% 3205

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Ameriprise's KYTX Position: Q4 2025 in Review

Ameriprise sold out of Kyverna Therapeutics (KYTX) in Q4 2025, closing a stake of 12,882 shares — an estimated $77.3K sold.

Ameriprise first reported a position in KYTX in Q1 2024 and held it in 5 quarters. The position peaked at $909K in Q1 2024. 99 funds tracked by Wall St. Rank hold KYTX as of Q4 2025.

  • Ameriprise reported no remaining Kyverna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 12,882 Kyverna Therapeutics shares in Q4 2025, an estimated $77.3K.
  • Ameriprise first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 5 quarters.
  • Ameriprise's Kyverna Therapeutics position peaked at $909K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.